China-based Everest Medicines (HKG: 1952) has announced the first patient dosing of an investigator-initiated clinical trial (IIT) for its personalized mRNA cancer vaccine, EVM16. The trial is designed to assess the safety, tolerability, immunogenicity, and preliminary efficacy of EVM16 alone or combined with a PD-1 inhibitor in advanced or recurrent solid tumors.
EVM16: A Novel Personalized Approach
EVM16 is a cutting-edge, personalized therapeutic mRNA cancer vaccine developed internally by Everest Medicines. The vaccine contains neoantigens with high immunogenicity potential, predicted using Everest’s proprietary AI-based neoantigen prediction algorithm, EVER-NEO-1. It is designed to encode dozens of tumor neoantigens, enabling the immune system to specifically target cancer cells. The use of a lipid nanoparticle (LNP) delivery system ensures efficient in vivo delivery of neoantigen-encoded mRNA, activating tumor-killing T cells and inhibiting tumor growth.
Clinical Trial Design
The trial is a dosage escalation and expansion study, intended to evaluate the safety and efficacy of EVM16 in patients with advanced or recurrent solid tumors. This marks a significant step forward in the development of personalized cancer treatments, offering hope for patients with limited therapeutic options.-Fineline Info & Tech
Leave a Reply